- GSK has submitted bepirovirsen to Health Canada for regulatory review under its priority review pathway for chronic hepatitis B (CHB)
- The investigational antisense oligonucleotide is supported by Phase 3 B-Well trials data showing statistically significant and clinically meaningful functional cure rates when added to standard of care
- Current CHB therapies often require lifelong treatment, while functional cure rates remain ~1%; Canada is estimated to have ~262K people living with chronic hepatitis B
- The filing adds to ongoing global regulatory submissions across the US, EU, China, and Japan, with bepirovirsen also receiving Breakthrough Therapy designation from the US FDA
Takeaways
Bepirovirsen’s Canada filing signals a coming shift in the hepatitis B market from lifelong viral suppression to time‑limited “functional cure” regimens, which could reshape how payers think about value and pricing in CHB.
If approved, a finite‑duration, add‑on therapy that delivers far higher cure rates than current drugs would pressure existing oral NA therapies, drive more screening and specialist referrals among the ~262,000 Canadians with chronic hepatitis B, and create a new high‑value specialty segment that GSK will try to scale globally off parallel submissions in the US, EU, China, and Japan under expedited pathways like FDA Breakthrough Therapy.
Source: CA Newswire
